There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI – Research Report), Hookipa Pharma (HOOK – Research Report) and Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) with bullish sentiments.
Trevi Therapeutics (TRVI)
In a report issued on November 9, Thomas Smith from Leerink Partners reiterated a Buy rating on Trevi Therapeutics, with a price target of $6.00. The company’s shares closed last Monday at $1.34, close to its 52-week low of $1.18.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Trevi Therapeutics is a Strong Buy with an average price target of $7.00, implying a 430.3% upside from current levels. In a report issued on November 2, JonesTrading also maintained a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Hookipa Pharma (HOOK)
In a report issued on November 9, Andrew Berens from Leerink Partners maintained a Buy rating on Hookipa Pharma, with a price target of $4.00. The company’s shares closed last Monday at $0.47, close to its 52-week low of $0.41.
According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Hookipa Pharma is a Strong Buy with an average price target of $6.13, an 1126.0% upside from current levels. In a report issued on November 10, H.C. Wainwright also maintained a Buy rating on the stock with a $6.50 price target.
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Leerink Partners analyst David Risinger reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR on November 10. The company’s shares closed last Monday at $54.67.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Structure Therapeutics, Inc. Sponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $87.40, representing a 61.9% upside. In a report issued on October 26, Piper Sandler also reiterated a Buy rating on the stock with a $93.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TRVI:
